Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.
about
Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancerIndividualized treatment of gastric cancer: Impact of molecular biology and pathohistological featuresTreatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical updateClinical utility of ramucirumab in advanced gastric cancerRamucirumab: preclinical research and clinical development.Ramucirumab: successfully targeting angiogenesis in gastric cancer.Clinical advances in the development of novel VEGFR2 inhibitors.Computational systems biology approaches to anti-angiogenic cancer therapeutics.Obesity-related known and candidate SNP markers can significantly change affinity of TATA-binding protein for human gene promoters.Candidate SNP markers of aggressiveness-related complications and comorbidities of genetic diseases are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters.PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled RamucirumabRamucirumab for the treatment of gastroesophageal cancers.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.Ramucirumab: first global approval.Clinical experience with ramucirumab : outcomes in breast cancer.Ramucirumab for gastric cancer.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Ramucirumab: A Review in Advanced Gastric Cancer.Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.Ramucirumab in the treatment of non-small cell lung cancer.Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis.Phage display-derived human antibodies in clinical development and therapy
P2860
Q26750715-37B51D22-4667-44D8-8296-68A957BC6DF9Q26776198-52DE70A5-4918-4BF3-B66D-2952396C7253Q26778004-3BA05A19-BECB-4208-8760-E1D426497191Q26785665-E4623B7B-7029-47D0-AAB7-099B45A97B45Q34446310-965E90FD-25D3-435F-A2B3-70C62B51E7A3Q34616558-43344BEA-E1CE-469B-ACA7-C08313535B6DQ34658366-649A0E2E-DE27-431F-9ECD-CA5220839575Q35108084-836A4F20-2FEC-4301-B415-731EE1568C3BQ35875387-2B921DA0-AA17-4F1D-A1E8-A75E0659EBCAQ36255004-ABC8BC6E-2F87-4A3D-A994-87ABC9E2FC78Q36535436-BFC3AD29-45D2-4965-B27C-9923D1B3A956Q37211153-1209A8B5-745B-41BA-8FCB-FCD5C9C98F16Q37708897-7F19093D-181D-4A5D-9ECA-14305F8D54E2Q38210070-55E8208D-61C8-452C-9524-24DB03BAFB59Q38219239-9B60B5CE-B793-41EB-913A-E34FF2180899Q38228982-B2ECB0E9-8665-4D21-92AD-4186A2585A22Q38272318-8CC738E9-A378-4609-80A3-AB2CC533E234Q38498207-1F001289-1826-42CF-BA0A-8EDA7539727DQ38581171-0F0E3BE7-0056-43EA-A2F7-A74112C00063Q38823193-79830DA4-AB42-4974-BB13-E2CFEA5FDE52Q38826507-2F281266-C8D8-4FF8-899D-E1BF68555B47Q39232340-355F3C0D-FC38-413D-94D4-996F259FD14FQ39368829-6180AF86-617B-43C4-BF15-1FD71D86BA95Q41416393-C604B2EF-2F42-4312-84AA-2B74EA7AB271
P2860
Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Critical appraisal of ramuciru ...... rom benchside to clinical use.
@en
type
label
Critical appraisal of ramuciru ...... rom benchside to clinical use.
@en
prefLabel
Critical appraisal of ramuciru ...... rom benchside to clinical use.
@en
P2093
P2860
P1433
P1476
Critical appraisal of ramuciru ...... from benchside to clinical use
@en
P2093
Elena Ongaro
Francesco Giuliani
Giuseppe Aprile
P2860
P2888
P304
P356
10.1007/S40265-013-0154-8
P577
2013-12-01T00:00:00Z
P6179
1017977311